论文部分内容阅读
目的:评价重组溶葡球菌酶对实验性皮肤烫伤耐甲氧西林金葡菌(MRSA)感染的抗感染作用。方法:用中国实验用小型猪建立局部皮肤烫伤后MRSA感染模型,不同处理组创面治疗3 d或7 d后,进行痂下组织活菌计数及组织病理学观察,评价药物抗菌疗效。结果:重组溶葡球菌酶对烫伤皮肤的感染细菌有较好的清除作用,治疗后d 4和d 8高浓度(1 000 U.mL-1)组创面活菌计数[(5.94±0.61)和(4.03±0.75)lg CFU.g-1组织]均明显低于空白对照组[(7.48±0.33)和(6.32±0.60)lg CFU.g-1组织]和阳性药SD-Ag组创面[(7.44±0.19)和(5.29±0.40)lg CFU.g-1组织],P<0.05或P<0.01;治疗后d 8,中浓度(330 U.mL-1)组创面活细菌计数[(5.10±0.29)lg CFU.g-1组织]明显低于空白对照组创面[(6.32±0.60)lg CFU.g-1组织],P<0.05。组织病理学观察也反映了重组溶葡球菌酶的良好疗效。结论:重组溶葡球菌酶对MRSA引起的实验性皮肤烫伤感染有良好的抗感染作用。
OBJECTIVE: To evaluate the anti-infective effect of recombinant lysostaphin on experimental skin scald S. aureus MRSA infection. Methods: The model of MRSA infection after partial skin scald was established in experimental mini-pigs in China. After 3 days or 7 days of wound healing in different treatment groups, viable count and histopathology of sub-callus tissue were observed to evaluate the antibacterial efficacy of the drug. Results: The recombinant lysostaphin had a good scavenging effect on the bacteria infected with scald skin. After treatment, the viable count ([5.94 ± 0.61] and [ (4.03 ± 0.75) lg CFU.g-1 tissues] were significantly lower than that of the blank control group [(7.48 ± 0.33) and (6.32 ± 0.60) 7.44 ± 0.19) and (5.29 ± 0.40) lg CFU.g-1 tissues], P <0.05 or P <0.01; ± 0.29) lg CFU.g-1 tissue] was significantly lower than the blank control group [(6.32 ± 0.60) lg CFU.g-1 tissue], P <0.05. Histopathological observations also reflect the good efficacy of recombinant lysostaphin. Conclusion: Recombinant lysostaphin has a good anti-infective effect on MRSA-induced experimental skin scald infection.